Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

Patrick K. Reville, Koji Sasaki, Hagop M. Kantarjian, Naval G. Daver, Musa Yilmaz, Courtney D. Dinardo, Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju, Rohtesh S. Mehta, Sherry Pierce, Sergej N. Konoplev, Joseph D. Khoury, Guillermo Garcia-Manero, Marina Y. Konopleva, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science